The top 5 targets (AKT1, IL6, TNF, TP53, IL-1β) and NLRP3 inflammasome-related targets (NLRP3, Caspase-1) in the PPI network were selected for molecular docking with key components (quercetin, kaempferol, (−) -catechin, beta-sitosterol, naringenin) to further determine the effectiveness of CA in the treatment of kidney stones. The gene discussed is TP53; the disease is nephrolithiasis.